Asthma drugs cut risk of CVD

Some asthma medications might help reduce cardiovascular risk and alleviate asthma symptoms, a US study has shown.

It found patients given low-dose theophylline add-on therapy or the leukotrine receptor antagonist montelukast for asthma had lower cardiovascular disease blood risk factors.

Both drugs are recommended by British Thoracic Society/SIGN guidelines for asthma patients who do not respond to long acting beta-2 agonists.

The study included 489 patients aged from 15-79 years who were diagnosed with asthma, but had an FEV1 greater than 50 per cent.

Dr Steve Holmes, Somerset GP and General Practice Airways Group (GPIAG) chairman said: 'This study looked very much at surrogate markers rather than actual outcomes.'

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus